Abdollah, F., Karnes, R. J., Suardi, N., Cozzarini, C., Gandaglia, G., Fossati, N., . . . Briganti, A. (2014). Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. Journal of Clinical Oncology, 32(35), 3939-3947. https://doi.org/10.1200/JCO.2013.54.7893
Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., . . . Scher, H. I. (2019). Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA oncology, 5(4), 471-478. https://doi.org/10.1001/jamaoncol.2018.5801
Aksnessæther, B. Y., Lund, J., Myklebust, T., Klepp, O. H., Skovlund, E., Roth Hoff, S., & Solberg, A. (2019). Second cancers in radically treated Norwegian prostate cancer patients. Acta Oncologica, 58(6), 838-844. https://doi.org/10.1080/0284186x.2019.1581377
Albertsen, P. C., Hanley, J. A., Gleason, D. F., & Barry, M. J. (1998). Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA, 280(11), 975-980. https://doi.org/10.1001/jama.280.11.975
Alsadius, D., Hedelin, M., Johansson, K. A., Pettersson, N., Wilderäng, U., Lundstedt, D., & Steineck, G. (2011). Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer. Radiotherapy and Oncology, 101(3), 495-501. https://doi.org/10.1016/j.radonc.2011.06.010
Amini, A., Jones, B. L., Yeh, N., Rusthoven, C. G., Armstrong, H., & Kavanagh, B. D. (2015). Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. International Journal of Radiation Oncology, Biology, Physics, 93(5), 1052-1063. https://doi.org/10.1016/j.ijrobp.2015.09.006
Andreyev, H. J., Wotherspoon, A., Denham, J. W., & Hauer-Jensen, M. (2010). Defining pelvic-radiation disease for the survivorship era. Lancet Oncology, 11(4), 310-312. https://doi.org/10.1016/s1470-2045(10)70026-7
Association of the Nordic Cancer Registries. (2017). NORDCAN – Kreftstatistikk for de nordiske landene. Version 8.0. [database]. [s.l.]: Association of the Nordic Cancer Registries. Danish Cancer Society. Hentet 20. februar.2017, fra http://www-dep.iarc.fr/nordcan.htm
Attard, G., Murphy, L., Clarke, N. W., Cross, W., Jones, R. J., Parker, C. C., . . . James, N. D. (2022). Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399(10323), 447-460. https://doi.org/10.1016/s0140-6736(21)02437-5
Bernard, J. R., Jr., Buskirk, S. J., Heckman, M. G., Diehl, N. N., Ko, S. J., Macdonald, O. K., . . . Pisansky, T. M. (2010). Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. International Journal of Radiation Oncology, Biology, Physics, 76(3), 735-740. https://doi.org/10.1016/j.ijrobp.2009.02.049
Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C., Oddens, J., Poortmans, P. M., . . . Collette, L. (2009). Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine, 360(24), 2516-2527. https://doi.org/10.1056/NEJMoa0810095
Brand, D. H., Tree, A. C., Ostler, P., van der Voet, H., Loblaw, A., Chu, W., . . . van As, N. (2019). Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, 20(11), 1531-1543. https://doi.org/10.1016/s1470-2045(19)30569-8
Bray, F., Lortet-Tieulent, J., Ferlay, J., Forman, D., & Auvinen, A. (2010). Prostate cancer incidence and mortality trends in 37 European countries: an overview. European Journal of Cancer, 46(17), 3040-3052. https://doi.org/10.1016/j.ejca.2010.09.013
Brierley, J. D., Gospodarowicz, M. K., & Wittekind, C. (red.). (2017). TNM classification of malignant tumors (8. utg.). Hoboken, NJ: John Wiley & Sons, Inc.
Briganti, A., Larcher, A., Abdollah, F., Capitanio, U., Gallina, A., Suardi, N., . . . Montorsi, F. (2012). Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. European Urology, 61(3), 480-487. https://doi.org/10.1016/j.eururo.2011.10.044
Bul, M., van den Bergh, R. C., Zhu, X., Rannikko, A., Vasarainen, H., Bangma, C. H., . . . Roobol, M. J. (2012). Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU International, 110(11), 1672-1677. https://doi.org/10.1111/j.1464-410X.2012.11434.x
Burdett, S., Boevé, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., . . . Tierney, J. F. (2019). Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology, 76(1), 115-124. https://doi.org/10.1016/j.eururo.2019.02.003
Bøhn, S. H., Fosså, S. D., Wisløff, T., & Thorsen, L. (2019). Physical activity and associations with treatment-induced adverse effects among prostate cancer patients. Supportive Care in Cancer, 27(3), 1001-1011. https://doi.org/10.1007/s00520-018-4389-5
Carrie, C., Hasbini, A., de Laroche, G., Richaud, P., Guerif, S., Latorzeff, I., . . . Dussart, S. (2016). Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncology, 17(6), 747-756. https://doi.org/10.1016/S1470-2045(16)00111-X
Catton, C. N., Lukka, H., Gu, C. S., Martin, J. M., Supiot, S., Chung, P. W. M., . . . Levine, M. N. (2017). Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 35(17), 1884-1890. https://doi.org/10.1200/jco.2016.71.7397
Caulfield, S., Menezes, G., Marignol, L., & Poole, C. (2018). Nomograms are key decision-making tools in prostate cancer radiation therapy. Urologic Oncology, 36(6), 283-292. https://doi.org/10.1016/j.urolonc.2018.03.017
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012). International variation in prostate cancer incidence and mortality rates. European Urology, 61(6), 1079-1092. https://doi.org/10.1016/j.eururo.2012.02.054
Chen, H., Ewing, C. M., Zheng, S., Grindedaal, E. M., Cooney, K. A., Wiley, K., . . . Isaacs, W. B. (2018). Genetic factors influencing prostate cancer risk in Norwegian men. Prostate, 78(3), 186-192. https://doi.org/10.1002/pros.23453
Cook, L. S., Goldoft, M., Schwartz, S. M., & Weiss, N. S. (1999). Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. Journal of Urology, 161(1), 152-155.
Cooperberg, M. R., Pasta, D. J., Elkin, E. P., Litwin, M. S., Latini, D. M., Du Chane, J., & Carroll, P. R. (2005). The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. Journal of Urology, 173(6), 1938-1942. https://doi.org/10.1097/01.ju.0000158155.33890.e7
Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., . . . Mottet, N. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. European Urology, 71(4), 630-642. https://doi.org/10.1016/j.eururo.2016.08.002
Cushman, T. R., Verma, V., Khairnar, R., Levy, J., Simone, C. B., 2nd, & Mishra, M. V. (2019). Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials. Oncotarget, 10(54), 5660-5668. https://doi.org/10.18632/oncotarget.27177
D'Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008). Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA, 299(3), 289-295. https://doi.org/10.1001/jama.299.3.289
Dall'Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., . . . Soloway, M. S. (2012). Active surveillance for prostate cancer: a systematic review of the literature. European Urology, 62(6), 976-983. https://doi.org/10.1016/j.eururo.2012.05.072
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., . . . Sartor, A. O. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376(9747), 1147-1154. https://doi.org/10.1016/s0140-6736(10)61389-x
de Wit, R., de Bono, J., Sternberg, C. N., Fizazi, K., Tombal, B., Wülfing, C., . . . Castellano, D. (2019). Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. New England Journal of Medicine, 381(26), 2506-2518. https://doi.org/10.1056/NEJMoa1911206
Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., . . . Hall, E. (2016). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology, 17(8), 1047-1060. https://doi.org/10.1016/s1470-2045(16)30102-4
Droz, J. P., Aapro, M., Balducci, L., Boyle, H., Van den Broeck, T., Cathcart, P., . . . Sugihara, T. (2014). Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncology, 15(9), e404-414. https://doi.org/10.1016/s1470-2045(14)70018-x
Eastham, J. A. (2007). Bone health in men receiving androgen deprivation therapy for prostate cancer. Journal of Urology, 177(1), 17-24. https://doi.org/10.1016/j.juro.2006.08.089
Edwards, S. M., Evans, D. G., Hope, Q., Norman, A. R., Barbachano, Y., Bullock, S., . . . Eeles, R. A. (2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. British Journal of Cancer, 103(6), 918-924. https://doi.org/10.1038/sj.bjc.6605822
Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., . . . Eeles, R. A. (2003). Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. American Journal of Human Genetics, 72(1), 1-12. https://doi.org/10.1086/345310
Eisenberger, M., Hardy-Bessard, A. C., Kim, C. S., Géczi, L., Ford, D., Mourey, L., . . . de Bono, J. (2017). Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. Journal of Clinical Oncology, 35(28), 3198-3206. https://doi.org/10.1200/jco.2016.72.1076
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . . Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228-247. https://doi.org/10.1016/j.ejca.2008.10.026
Epstein, J. I., Amin, M. B., Reuter, V. E., & Humphrey, P. A. (2017). Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 41(4), e1-e7. https://doi.org/10.1097/pas.0000000000000820
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016). The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. American Journal of Surgical Pathology, 40(2), 244-252. https://doi.org/10.1097/pas.0000000000000530
European Commission. (20. september 2022). European Health Union: A new EU approach on cancer detection – screening more and screening better. [nettdokument]. Brussel: European Commission. Hentet 06. januar 2023, fra https://ec.europa.eu/commission/presscorner/detail/en/ip_22_5562
Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., . . . Cooney, K. A. (2012). Germline mutations in HOXB13 and prostate-cancer risk. New England Journal of Medicine, 366(2), 141-149. https://doi.org/10.1056/NEJMoa1110000
Extermann, M., Boler, I., Reich, R. R., Lyman, G. H., Brown, R. H., DeFelice, J., . . . Balducci, L. (2012). Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer, 118(13), 3377-3386. https://doi.org/10.1002/cncr.26646
Fanti, S., Goffin, K., Hadaschik, B. A., Herrmann, K., Maurer, T., MacLennan, S., . . . Bjartell, A. (2021). Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48(2), 469-476. https://doi.org/10.1007/s00259-020-04934-4
Ficarra, V., Novara, G., Rosen, R. C., Artibani, W., Carroll, P. R., Costello, A., . . . Mottrie, A. (2012). Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. European Urology, 62(3), 405-417. https://doi.org/10.1016/j.eururo.2012.05.045
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., . . . Goessl, C. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813-822. https://doi.org/10.1016/s0140-6736(10)62344-6
Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., . . . Bossi, A. (2022). Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet, 399(10336), 1695-1707. https://doi.org/10.1016/s0140-6736(22)00367-1
Fizazi, K., Shore, N. D., Tammela, T., Ulys, A., Vjaters, E., Polyakov, S., . . . Smith, M. R. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5514. https://doi.org/10.1200/JCO.2020.38.15_suppl.5514
Focal Prostate Ablation Versus Radical Prostatectomy (FARP). (2017-2024). [pågående studie]. (NCT03668652). Hentet fra https://clinicaltrials.gov/ct2/show/NCT03668652
Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). (2000). FOR-2000-12-01-1208. Sist endret i FOR-2020-02-04-119 fra 01.03.2020. Hentet fra https://lovdata.no/dokument/SF/forskrift/2000-12-01-1208
Fossati, N., Willemse, P. M., Van den Broeck, T., van den Bergh, R. C. N., Yuan, C. Y., Briers, E., . . . Joniau, S. (2017). The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. European Urology, 72(1), 84-109. https://doi.org/10.1016/j.eururo.2016.12.003
Fransson, P., Nilsson, P., Gunnlaugsson, A., Beckman, L., Tavelin, B., Norman, D., . . . Widmark, A. (2021). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncology, 22(2), 235-245. https://doi.org/10.1016/s1470-2045(20)30581-7
Gandaglia, G., Trinh, Q. D., Hu, J. C., Schiffmann, J., Becker, A., Roghmann, F., . . . Abdollah, F. (2014). The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination" period. European Journal of Surgical Oncology, 40(9), 1080-1086. https://doi.org/10.1016/j.ejso.2013.12.016
Gjerset, G. M., Kiserud, C. E., Loge, J. H., Fosså, S. D., Wisløff, T., Gudbergsson, S. B., . . . Thorsen, L. (2019). Changes in fatigue, health-related quality of life and physical activity after a one-week educational program for cancer survivors. Acta Oncologica, 58(5), 682-689. https://doi.org/10.1080/0284186x.2018.1562210
Graff, J. N., & Beer, T. M. (2014). Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs and Aging, 31(12), 873-882. https://doi.org/10.1007/s40266-014-0224-y
Grindedal, E. M., Møller, P., Eeles, R., Stormorken, A. T., Bowitz-Lothe, I. M., Landrø, S. M., . . . Maehle, L. (2009). Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiology, Biomarkers and Prevention, 18(9), 2460-2467. https://doi.org/10.1158/1055-9965.Epi-09-0058
Haglind, E., Carlsson, S., Stranne, J., Wallerstedt, A., Wilderäng, U., Thorsteinsdottir, T., . . . Steineck, G. (2015). Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. European Urology, 68(2), 216-225. https://doi.org/10.1016/j.eururo.2015.02.029
Hall, W. A., Paulson, E., Davis, B. J., Spratt, D. E., Morgan, T. M., Dearnaley, D., . . . Lawton, C. A. F. (2021). NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 109(1), 174-185. https://doi.org/10.1016/j.ijrobp.2020.08.034
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., . . . Neal, D. E. (2016). 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 375(15), 1415-1424. https://doi.org/10.1056/NEJMoa1606220
Haque, R., UlcickasYood, M., Xu, X., Cassidy-Bushrow, A. E., Tsai, H. T., Keating, N. L., . . . Potosky, A. L. (2017). Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. British Journal of Cancer, 117(8), 1233-1240. https://doi.org/10.1038/bjc.2017.280
Helse- og omsorgsdepartementet. (2015). Nasjonal helse- og sykehusplan (2016−2019) (Meld. St. 11 (2015–2016)). Hentet fra https://www.regjeringen.no/contentassets/7b6ad7e0ef1a403d97958bcb34478609/no/pdfs/stm201520160011000dddpdfs.pdf
Helsedirektoratet. (2015). Kreftkirurgi i Norge (IS-2284). Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/rapporter/kreftkirurgi-i-norge?download=false
Helsedirektoratet. (2. august 2018). Prostatakreft. I: Pakkeforløp for kreft: diagnoseveiledere. [nettdokument]. Oslo: Helsedirektoratet. Hentet 3. oktober 2022, fra https://www.helsedirektoratet.no/nasjonale-forlop/pakkeforlop-for-kreft-diagnoseveiledere/diagnoseveiledere#prostatakreft
Helsedirektoratet. (14. oktober 2019). Nasjonalt handlingsprogram for palliasjon i kreftomsorgen. [nettdokument]. Oslo: Helsedirektoratet. Hentet 3. november 2020, fra https://www.helsedirektoratet.no/retningslinjer/palliasjon-i-kreftomsorgen-handlingsprogram
Helsedirektoratet. (2020). Seneffekter etter kreftbehandling (IS-2872). Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/rapporter/seneffekter-etter-kreftbehandling
Helsedirektoratet. (29. april 2022). Prostatakreft: pakkeforløp. [nettdokument]. Oslo: Helsedirektoratet. Hentet 03.10.2022, fra https://www.helsedirektoratet.no/pakkeforlop/prostatakreft
Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., . . . Shapiro, C. L. (2017). Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA, 317(1), 48-58. https://doi.org/10.1001/jama.2016.19425
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., . . . Auvinen, A. (2019). A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 76(1), 43-51. https://doi.org/10.1016/j.eururo.2019.02.009
Ilic, D., O'Connor, D., Green, S., & Wilt, T. J. (2011). Screening for prostate cancer: an updated Cochrane systematic review. BJU International, 107(6), 882-891. https://doi.org/10.1111/j.1464-410X.2010.10032.x
Ip, S., Dahabreh, I. J., Chung, M., Yu, W. W., Balk, E. M., Iovin, R. C., . . . Lau, J. (2011). An evidence review of active surveillance in men with localized prostate cancer. Evidence report/technology assessment, (204), 1-341.
Italiano, A., Ortholan, C., Oudard, S., Pouessel, D., Gravis, G., Beuzeboc, P., . . . Fizazi, K. (2009). Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. European Urology, 55(6), 1368-1375. https://doi.org/10.1016/j.eururo.2008.07.078
Jackson, W. C., Silva, J., Hartman, H. E., Dess, R. T., Kishan, A. U., Beeler, W. H., . . . Spratt, D. E. (2019). Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology, Biology, Physics, 104(4), 778-789. https://doi.org/10.1016/j.ijrobp.2019.03.051
James, N. D., Clarke, N. W., Cook, A., Ali, A., Hoyle, A. P., Attard, G., . . . Sydes, M. R. (2022). Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 151(3), 422-434. https://doi.org/10.1002/ijc.34018
James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., Mason, M. D., Parker, C. C., . . . Sydes, M. R. (2016). Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA oncology, 2(3), 348-357. https://doi.org/10.1001/jamaoncol.2015.4350
Joseph, D., Denham, J. W., Steigler, A., Lamb, D. S., Spry, N. A., Stanley, J., . . . Attia, J. (2020). Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. International Journal of Radiation Oncology, Biology, Physics, 106(4), 693-702. https://doi.org/10.1016/j.ijrobp.2019.11.415
Karlsson, R., Aly, M., Clements, M., Zheng, L., Adolfsson, J., Xu, J., . . . Wiklund, F. (2014). A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. European Urology, 65(1), 169-176. https://doi.org/10.1016/j.eururo.2012.07.027
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24(27), 4448-4456. https://doi.org/10.1200/jco.2006.06.2497
Kellokumpu-Lehtinen, P. L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., . . . Joensuu, H. (2013). 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncology, 14(2), 117-124. https://doi.org/10.1016/s1470-2045(12)70537-5
Kishan, A. U., Cook, R. R., Ciezki, J. P., Ross, A. E., Pomerantz, M. M., Nguyen, P. L., . . . King, C. R. (2018). Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA, 319(9), 896-905. https://doi.org/10.1001/jama.2018.0587
Korfage, I. J., Essink-Bot, M. L., Borsboom, G. J., Madalinska, J. B., Kirkels, W. J., Habbema, J. D., . . . de Koning, H. J. (2005). Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. International Journal of Cancer, 116(2), 291-296. https://doi.org/10.1002/ijc.21043
Kote-Jarai, Z., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Castro, E., Mahmud, N., . . . Eeles, R. (2011). BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. British Journal of Cancer, 105(8), 1230-1234. https://doi.org/10.1038/bjc.2011.383
Kvåle, R., Myklebust, T., Engholm, G., Heinävaara, S., Wist, E., & Møller, B. (2017). Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013. International Journal of Cancer, 141(11), 2228-2242. https://doi.org/10.1002/ijc.30924
Kyrdalen, A. E., Dahl, A. A., Hernes, E., Cvancarova, M., & Fosså, S. D. (2010). Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer and Prostatic Diseases, 13(2), 144-150. https://doi.org/10.1038/pcan.2009.61
Larsen, I. K. (red.). (2020). Cancer in Norway 2019: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/Generelt/Rapporter/Cancer-in-Norway/cancer-in-norway-2019/
Lawton, C. A., DeSilvio, M., Roach, M., Uhl, V., Kirsch, R., Seider, M., . . . Thomas, C. R. (2007). An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. International Journal of Radiation Oncology, Biology, Physics, 69(3), 646-655. https://doi.org/10.1016/j.ijrobp.2007.04.003
Lawton, C. A., Winter, K., Grignon, D., & Pilepich, M. V. (2005). Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. Journal of Clinical Oncology, 23(4), 800-807. https://doi.org/10.1200/jco.2005.08.141
Lehrer, E. J., Kishan, A. U., Yu, J. B., Trifiletti, D. M., Showalter, T. N., Ellis, R., & Zaorsky, N. G. (2020). Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy and Oncology, 148, 235-242. https://doi.org/10.1016/j.radonc.2020.04.037
Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., . . . Kote-Jarai, Z. (2012). Germline BRCA1 mutations increase prostate cancer risk. British Journal of Cancer, 106(10), 1697-1701. https://doi.org/10.1038/bjc.2012.146
Lorente, D., Omlin, A., Ferraldeschi, R., Pezaro, C., Perez, R., Mateo, J., . . . Attard, G. (2014). Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. British Journal of Cancer, 111(12), 2248-2253. https://doi.org/10.1038/bjc.2014.531
Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). (1999). LOV-1999-07-02-63. Sist endret i LOV-2019-12-20-104 fra 01.03.2020. Hentet fra https://lovdata.no/dokument/NL/lov/1999-07-02-63
MacInnis, R. J., Severi, G., Baglietto, L., Dowty, J. G., Jenkins, M. A., Southey, M. C., . . . Giles, G. G. (2013). Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E. PloS One, 8(2), e54727. https://doi.org/10.1371/journal.pone.0054727
Moch, H., Humphrey, P. A., & Ulbright, T. M. (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs (4. utg.). (WHO Classification of Tumours, Volume 8). Lyon: International Agency for Research on Cancer;.
Morash, C., Tey, R., Agbassi, C., Klotz, L., McGowan, T., Srigley, J., & Evans, A. (2015). Active surveillance for the management of localized prostate cancer: Guideline recommendations. Canadian Urological Association journal, 9(5-6), 171-178. https://pubmed.ncbi.nlm.nih.gov/26225165/
Morris, W. J., Tyldesley, S., Rodda, S., Halperin, R., Pai, H., McKenzie, M., . . . Murray, N. (2017). Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 98(2), 275-285. https://doi.org/10.1016/j.ijrobp.2016.11.026
Moschini, M., Carroll, P. R., Eggener, S. E., Epstein, J. I., Graefen, M., Montironi, R., & Parker, C. (2017). Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 72(2), 238-249. https://doi.org/10.1016/j.eururo.2017.03.009
Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., . . . André, F. (2020). Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 31(11), 1491-1505. https://doi.org/10.1016/j.annonc.2020.07.014
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., . . . Cornford, P. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 71(4), 618-629. https://doi.org/10.1016/j.eururo.2016.08.003
Mottet, N., Cornford, P., van den Bergh, R. C. N., Briers, E., Santis, M. D., Fanti, S., . . . Wiegel, T. (2020). EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer (rev. utg.). Arnhem: European Association of Urology. Hentet fra https://uroweb.org/guideline/prostate-cancer/
Mulders, P. F., Molina, A., Marberger, M., Saad, F., Higano, C. S., Chi, K. N., . . . Fizazi, K. (2014). Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. European Urology, 65(5), 875-883. https://doi.org/10.1016/j.eururo.2013.09.005
Murthy, V., Maitre, P., Kannan, S., Panigrahi, G., Krishnatry, R., Bakshi, G., . . . Mahantshetty, U. (2021). Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 39(11), 1234-1242. https://doi.org/10.1200/jco.20.03282
Nasjonalt kvalitetsregister for prostatakreft. (2017). Årsrapport 2016 med resultater og forbedringstiltak. Oslo: Kreftregisteret. Hentet fra https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2017/arsrapport-2016_prostatakreft.pdf
Nasjonalt kvalitetsregister for prostatakreft. (2022). Årsrapport 2021; Resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft. Oslo: Kreftregisteret. Hentet fra https://www.kvalitetsregistre.no/sites/default/files/2022-06/%C3%85rsrapport%202021%20Nasjonalt%20kvalitetsregister%20for%20prostatakreft.pdf
National Comprehensive Cancer Network. (2018). NCCN Guidelines Prostate Cancer. Plymouth Meeting, PA: NCCN.
Norsk revmatologisk forening. (01. mai 2022). Osteoporose. Versjon 0.12. I: Revmatologi (NRF): nasjonal veileder. [nettdokument]. Oslo: Norsk revmatologisk forening. Hentet 30. september 2022, fra https://metodebok.no/index.php?action=topic&item=AtEEtJ7q
Novara, G., Ficarra, V., Mocellin, S., Ahlering, T. E., Carroll, P. R., Graefen, M., . . . Wilson, T. G. (2012a). Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. European Urology, 62(3), 382-404. https://doi.org/10.1016/j.eururo.2012.05.047
Novara, G., Ficarra, V., Rosen, R. C., Artibani, W., Costello, A., Eastham, J. A., . . . Wilson, T. G. (2012b). Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. European Urology, 62(3), 431-452. https://doi.org/10.1016/j.eururo.2012.05.044
Odisho, A. Y., Washington, S. L., 3rd, Meng, M. V., Cowan, J. E., Simko, J. P., & Carroll, P. R. (2013). Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology, 82(1), 154-159. https://doi.org/10.1016/j.urology.2012.12.063
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., . . . De Meerleer, G. (2018). Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 36(5), 446-453. https://doi.org/10.1200/jco.2017.75.4853
Oudard, S., Fizazi, K., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., . . . Sartor, O. (2017). Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. Journal of Clinical Oncology, 35(28), 3189-3197. https://doi.org/10.1200/jco.2016.72.1068
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., . . . Sartor, O. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 369(3), 213-223. https://doi.org/10.1056/NEJMoa1213755
Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., . . . Sydes, M. R. (2018). Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), 2353-2366. https://doi.org/10.1016/s0140-6736(18)32486-3
Penson, D. F., & Litwin, M. S. (2003). Quality of life after treatment for prostate cancer. Current urology reports, 4(3), 185-195. https://doi.org/10.1007/s11934-003-0068-1
Petersen, L. J., Nielsen, J. B., Langkilde, N. C., Petersen, A., Afshar-Oromieh, A., De Souza, N. M., . . . Zacho, H. D. (2020). (68)Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. World Journal of Urology, 38(4), 939-948. https://doi.org/10.1007/s00345-019-02846-z
Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., . . . Crawford, E. D. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine, 351(15), 1513-1520. https://doi.org/10.1056/NEJMoa041318
Pfister, D., Bolla, M., Briganti, A., Carroll, P., Cozzarini, C., Joniau, S., . . . Zelefsky, M. J. (2014). Early salvage radiotherapy following radical prostatectomy. European Urology, 65(6), 1034-1043. https://doi.org/10.1016/j.eururo.2013.08.013
Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., . . . Tran, P. T. (2020). Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA oncology, 6(5), 650-659. https://doi.org/10.1001/jamaoncol.2020.0147
Pillay, B., Wootten, A. C., Crowe, H., Corcoran, N., Tran, B., Bowden, P., . . . Costello, A. J. (2016). The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews, 42, 56-72. https://doi.org/10.1016/j.ctrv.2015.11.007
Popiolek, M., Rider, J. R., Andrén, O., Andersson, S. O., Holmberg, L., Adami, H. O., & Johansson, J. E. (2013). Natural history of early, localized prostate cancer: a final report from three decades of follow-up. European Urology, 63(3), 428-435. https://doi.org/10.1016/j.eururo.2012.10.002
Resnick, M. J., Koyama, T., Fan, K. H., Albertsen, P. C., Goodman, M., Hamilton, A. S., . . . Penson, D. F. (2013). Long-term functional outcomes after treatment for localized prostate cancer. New England Journal of Medicine, 368(5), 436-445. https://doi.org/10.1056/NEJMoa1209978
Rider, J. R., Sandin, F., Andrén, O., Wiklund, P., Hugosson, J., & Stattin, P. (2013). Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. European Urology, 63(1), 88-96. https://doi.org/10.1016/j.eururo.2012.08.001
Roach, M., 3rd, Hanks, G., Thames, H., Jr., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006). Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics, 65(4), 965-974. https://doi.org/10.1016/j.ijrobp.2006.04.029
Rush, H. L., Murphy, L., Morgans, A. K., Clarke, N. W., Cook, A. D., Attard, G., . . . Langley, R. E. (2022). Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. Journal of Clinical Oncology, 40(8), 825-836. https://doi.org/10.1200/jco.21.00728
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., . . . Krause, B. J. (2021). Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 385(12), 1091-1103. https://doi.org/10.1056/NEJMoa2107322
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., . . . Armstrong, A. J. (2016). Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 34(12), 1402-1418. https://doi.org/10.1200/jco.2015.64.2702
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V., . . . Erspc Investigators. (2014). Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, 384(9959), 2027-2035. https://doi.org/10.1016/S0140-6736(14)60525-0
Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., . . . Seymour, L. (2016). RECIST 1.1-Update and clarification: From the RECIST committee. European Journal of Cancer, 62, 132-137. https://doi.org/10.1016/j.ejca.2016.03.081
Schwarzenboeck, S. M., Rauscher, I., Bluemel, C., Fendler, W. P., Rowe, S. P., Pomper, M. G., . . . Eiber, M. (2017). PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 58(10), 1545-1552. https://doi.org/10.2967/jnumed.117.191031
Scott, R., Misser, S. K., Cioni, D., & Neri, E. (2021). PI-RADS v2.1: What has changed and how to report. SA journal of radiology, 25(1), 2062. https://doi.org/10.4102/sajr.v25i1.2062
Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., . . . RTOG, N. R. G. O. (2017). Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. New England Journal of Medicine, 376(5), 417-428. https://doi.org/10.1056/NEJMoa1607529
Siegmann, A., Bottke, D., Faehndrich, J., Lohm, G., Miller, K., Bartkowiak, D., . . . Hinkelbein, W. (2011). Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlentherapie und Onkologie, 187(8), 467-472. https://doi.org/10.1007/s00066-011-2229-3
Simpkin, A. J., Tilling, K., Martin, R. M., Lane, J. A., Hamdy, F. C., Holmberg, L., . . . Donovan, J. L. (2015). Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. European Urology, 67(6), 993-1005. https://doi.org/10.1016/j.eururo.2015.01.004
Small, E. J., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., . . . Smith, M. R. (2020). Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5516. https://doi.org/10.1200/JCO.2020.38.15_suppl.5516
Smith, M. R., Halabi, S., Ryan, C. J., Hussain, A., Vogelzang, N., Stadler, W., . . . Small, E. J. (2014). Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). Journal of Clinical Oncology, 32(11), 1143-1150. https://doi.org/10.1200/jco.2013.51.6500
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., . . . Tombal, B. (2022). Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 386(12), 1132-1142. https://doi.org/10.1056/NEJMoa2119115
Sonpavde, G., Pond, G. R., Armstrong, A. J., Galsky, M. D., Leopold, L., Wood, B. A., . . . Michaelson, M. D. (2014). Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU International, 114(6b), E25-e31. https://doi.org/10.1111/bju.12589
Steineck, G., Bjartell, A., Hugosson, J., Axén, E., Carlsson, S., Stranne, J., . . . Wiklund, P. (2015). Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery. European Urology, 67(3), 559-568. https://doi.org/10.1016/j.eururo.2014.10.011
Stensvold, A., Dahl, A. A., Brennhovd, B., Småstuen, M. C., Fosså, S. D., Lilleby, W., . . . Smeland, S. (2013). Bother problems in prostate cancer patients after curative treatment. Urologic Oncology, 31(7), 1067-1078. https://doi.org/10.1016/j.urolonc.2011.12.020
Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., Giorgi, U. D., Penson, D. F., . . . Hussain, M. H. A. (2020). Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5515. https://doi.org/10.1200/JCO.2020.38.15_suppl.5515
Stish, B. J., Pisansky, T. M., Harmsen, W. S., Davis, B. J., Tzou, K. S., Choo, R., & Buskirk, S. J. (2016). Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. Journal of Clinical Oncology, 34(32), 3864-3871. https://doi.org/10.1200/JCO.2016.68.3425
Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer (SPCG-15). (2017-2027). [pågående studie]. (NCT02102477). Hentet fra https://clinicaltrials.gov/ct2/show/NCT02102477
Sweeney, C. J., Chen, Y. H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., . . . DiPaola, R. S. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 373(8), 737-746. https://doi.org/10.1056/NEJMoa1503747
Sydes, M. R., Spears, M. R., Mason, M. D., Clarke, N. W., Dearnaley, D. P., de Bono, J. S., . . . James, N. D. (2018). Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), 1235-1248. https://doi.org/10.1093/annonc/mdy072
Syse, A., Pham, D. Q., & Keilman, N. (2016). Befolkningsframskrivinger 2016 - 2100: Dødelighet og levealder. Økonomiske analyser, (3), 25-36.
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., . . . Chen, B. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94(19), 1458-1468. https://doi.org/10.1093/jnci/94.19.1458
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., . . . Eisenberger, M. A. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502-1512. https://doi.org/10.1056/NEJMoa040720
Thorsen, L., Nilsen, T. S., Raastad, T., Courneya, K. S., Skovlund, E., & Fosså, S. D. (2012). A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design. BMC Cancer, 12, 123. https://doi.org/10.1186/1471-2407-12-123
Thostrup, M., Thomsen, F. B., Iversen, P., & Brasso, K. (2018). Active surveillance for localized prostate cancer: update of a prospective single-center cohort. Scandinavian Journal of Urology, 52(1), 14-19. https://doi.org/10.1080/21681805.2017.1380697
Tikkinen, K. A. O., Cartwright, R., Gould, M. K., Naspro, R., Novara, G., Sandset, P. M., . . . Guyatt, G. H. (2018). EAU Guidelines on Thromboprophylaxis in Urological Surgery. Arnhem: European Association of Urology. Hentet fra https://uroweb.org/guideline/thromboprophylaxis/
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87-108. https://doi.org/10.3322/caac.21262
Toussi, A., Stewart-Merrill, S. B., Boorjian, S. A., Psutka, S. P., Thompson, R. H., Frank, I., . . . Karnes, R. J. (2016). Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? Journal of Urology, 195(6), 1754-1759. https://doi.org/10.1016/j.juro.2015.12.075
van As, N., & Tree, A. (2020). The PACE Trial (Prostate Advances in Comparative Evidence): International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer: radiotherapy plannng and delivery guidelines (PACE-A and PACE-C) (Version: 2.0 utg.). London: Royal Marsden Hospital. Hentet fra https://d1ijoxngr27nfi.cloudfront.net/docs/default-source/default-document-library/pace_c_rtqaguidelines_v2-0-(04-march-2020).pdf?sfvrsn=dd202169_4
van den Bergh, R. C., Albertsen, P. C., Bangma, C. H., Freedland, S. J., Graefen, M., Vickers, A., & van der Poel, H. G. (2013). Timing of curative treatment for prostate cancer: a systematic review. European Urology, 64(2), 204-215. https://doi.org/10.1016/j.eururo.2013.02.024
van der Poel, H., van der Kwast, T., Aben, K., Mottet, N., & Mason, M. (2020). Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification. European Urology Oncology, 3(5), 563-564. https://doi.org/10.1016/j.euo.2019.06.001
van der Wielen, G. J., Mulhall, J. P., & Incrocci, L. (2007). Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiotherapy and Oncology, 84(2), 107-113. https://doi.org/10.1016/j.radonc.2007.07.018
Vatne, K., Stensvold, A., Myklebust, T., Møller, B., Svindland, A., Kvåle, R., & Fosså, S. D. (2017). Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. Acta Oncologica, 56(10), 1295-1301. https://doi.org/10.1080/0284186x.2017.1314006
Venkitaraman, R., Lorente, D., Murthy, V., Thomas, K., Parker, L., Ahiabor, R., . . . Parker, C. (2015). A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. European Urology, 67(4), 673-679. https://doi.org/10.1016/j.eururo.2014.10.004
Ventimiglia, E., Seisen, T., Abdollah, F., Briganti, A., Fonteyne, V., James, N., . . . Cheng, L. (2019). A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. European Urology Oncology, 2(3), 294-301. https://doi.org/10.1016/j.euo.2019.02.001
Viste, E., Vinje, C. A., Lid, T. G., Skeie, S., Evjen-Olsen, Ø., Nordström, T., . . . Kjosavik, S. R. (2020). Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. Scandinavian Journal of Primary Health Care, 38(3), 315-322. https://doi.org/10.1080/02813432.2020.1802139
Wallerstedt, A., Tyritzis, S. I., Thorsteinsdottir, T., Carlsson, S., Stranne, J., Gustafsson, O., . . . Haglind, E. (2015). Short-term results after robot-assisted laparoscopic radical prostatectomy compared to open radical prostatectomy. European Urology, 67(4), 660-670. https://doi.org/10.1016/j.eururo.2014.09.036
Walz, J., Epstein, J. I., Ganzer, R., Graefen, M., Guazzoni, G., Kaouk, J., . . . Artibani, W. (2016). A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update. European Urology, 70(2), 301-311. https://doi.org/10.1016/j.eururo.2016.01.026
Watson, M. J., George, A. K., Maruf, M., Frye, T. P., Muthigi, A., Kongnyuy, M., . . . Pinto, P. A. (2016). Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncology (London, England), 12(21), 2417-2430. https://doi.org/10.2217/fon-2016-0178
Widmark, A., Gunnlaugsson, A., Beckman, L., Thellenberg-Karlsson, C., Hoyer, M., Lagerlund, M., . . . Nilsson, P. (2019). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet, 394(10196), 385-395. https://doi.org/10.1016/s0140-6736(19)31131-6
Widmark, A., Klepp, O., Solberg, A., Damber, J. E., Angelsen, A., Fransson, P., . . . Fosså, S. D. (2009). Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet, 373(9660), 301-308. https://doi.org/10.1016/s0140-6736(08)61815-2
Win, A. K., Lindor, N. M., Young, J. P., Macrae, F. A., Young, G. P., Williamson, E., . . . Jenkins, M. A. (2012). Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. Journal of the National Cancer Institute, 104(18), 1363-1372. https://doi.org/10.1093/jnci/djs351
Wood, L. J., Nail, L. M., Gilster, A., Winters, K. A., & Elsea, C. R. (2006). Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncology Nursing Forum, 33(3), 535-542. https://doi.org/10.1188/06.Onf.535-542
Yu, E. Y., Gillessen, S., & Mottet, N. (2019). What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. European urology focus, 5(2), 162-164. https://doi.org/10.1016/j.euf.2018.09.015
Østerø Í Jákupsstovu, J., & Brodersen, J. (2018). Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? BMJ, 361, k1202. https://doi.org/10.1136/bmj.k1202